Mibolerone is a steroid and nandrolone derivative, it was first described in 1963. It is so strong that it is almost unsuitable for human use. In synthetic terms, it is 41 times more anabolic than methylated testosterone and 18 times more androgenic. As one of the few AAS, the dosage is expressed in micrograms, not milligrams. It is so toxic that it is not suitable for use in cats – it causes disturbances in the functioning of the thyroid gland, increases the amount of cholesterol and possibly uterine disease. It has been studied for use as a contraceptive in animals. More details here: https://anabolicmenu.ws/global-anabolic-cheque-drops-500/

Mibolerone is an extremely strong androgen, it aromatizes strongly with creating 7.17 dimethylestradiol. It also affects progesterone – which can have typical side effects: gynecomastia, increased water retention, hypertension, etc. with mibolerone outweigh the costs – and the risks and injuries do not balance the results. The toxicity of mibolerone is influenced by the methyl group at C17 (effect on the liver) and at C7 (androgenicity).

Experimentally, mibolerone can be used in the treatment of breast cancer in women. The signalling pathway mediated by androgens through androgen receptors is crucial for the growth of healthy and altered breast cells. One study compared the effects of 5-alpha-DHT and mibolerone on the estradiol-induced growth of breast cancer cells. DHT had a moderate effect on proliferation, while mibolerone had a very strong effect on T-47D cells. The action of both agents may have been inhabited by an androgen receptor antagonist (e.g. hydroxyflutamide), which suggests that the effects of both agents are at least partly due to an effect on androgen receptors. Additionally, it has been established that mibolerone also acts through progesterone receptors. In cells that lacked the progesterone receptor and had the androgen receptor (MCF-7 type), mibolerone had a moderate effect, however, it had a much greater effect in AR + and PR + cells (7M11 PRA type). Overall, mibolerone influenced breast cancer cells in a similar way to progesterone and medroxyprogesterone acetate.More details on the website: https://anabolicmenu.ws/

Common side effects of using mibolerone:

  • aggression,
  • strong virilization in women,
  • strong hepatotoxicity, especially if methanabol, Winstrol, oxymetholone (anapolone), oral turinabol, oxandrolone, R1881, superdrol, methyldienolone, 1-androsterone and other “safe prohormones” are used simultaneously; it is also dangerous to consume alcohol, other drugs that affect the liver,
  • change in blood lipid profile,
  • water retention, oedema (especially in middle-aged people),
  • increased conversion to estrogens (aromatization), note: the phenomenon is much more intense in men over 60 years of age!
  • increase in hematocrit; note: the phenomenon is much more intense in men over 60 years of age!
  • gynecomastia (if the athlete has a predisposition, he does not use aromatization control agents; note: as a rule, excessive estrogen levels are correlated with prolactin levels – and both hormones can cause gynecomastia!),
  • inhibition of testosterone production in the testes, blockage of the HPTA axis, effect on LH and FSH,
  • weight gain (also indirectly through water retention),
  • increasing libido (an individual matter, correlated, among others with the level of estrogens),
  • temporary or permanent infertility,
  • acne, oily skin,
  • hair loss, alopecia (genetically determined, the effect of testosterone conversion to DHT).

Assuming all these facts, we cannot call Cheque drops a popular steroid due to their side effects. It also causes serious mood changes, leading to aggression after its usage.